Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 5/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 4/20 | 0.43 |
| ▸ | EDNRA | P25101 | 4/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | YWHAH | Q04917 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091132 | 0.98 | PTGES (0.55) | PTGESTP53POLBSERPINE1S1PR3 | |
| SCHEMBL6091214 | 0.95 | PTGES (0.51) | PTGESTP53POLBSERPINE1S1PR3 | |
| SCHEMBL6091968 | 0.95 | PTGES (0.52) | PTGESTP53POLBSERPINE1S1PR3 | |
| SCHEMBL6091802 | 0.91 | PTGES (0.50) | PTGESTP53POLBS1PR3EDNRB | |
| SCHEMBL5739167 | 0.88 | PTGES (0.46) | PTGESSERPINE1EDNRBEDNRAMAPK8 | |
| SCHEMBL5738857 | 0.85 | SERPINE1 (0.56) | PTGESTP53POLBSERPINE1EDNRB | |
| SCHEMBL6089483 | 0.82 | TP53 (0.44) | PTGESTP53POLBS1PR3P2RX3 | |
| SCHEMBL6091644 | 0.82 | PTGES (0.51) | PTGESPOLBSERPINE1EDNRBEDNRA | |
| SCHEMBL6091691 | 0.81 | TP53 (0.44) | PTGESTP53POLBS1PR3P2RX3 | |
| SCHEMBL6091379 | 0.81 | YWHAH (0.45) | PTGESTP53POLBYWHAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | IDO1, PTGS1, IDO2 | PTGES 4/4885TP53 2032/4885POLB 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.